The ADMA (Asymmetric Dimethylarginine) ELISA Assay Kit is intended for the quantitative determination of ADMA (Asymmetric Dimethylarginine) in serum or plasma.  The Eagle Biosciences ADMA (Asymmetric Dimethylarginine) ELISA Assay Kit is for research use only and not to be used in clinical, therapeutic or diagnostic procedures.
This product was previously known as ADM31-K01.


ADMA ELISA Assay Kit is developed and manufactured in Germany by DLD Diagnostika EA212/96 (Previously EA201/96)

For Research Use Only

Size: 1×96 wells
Sensitivity: 0.03 µmol/L
Dynamic Range: 0.2 – 3.0 µmol/L
Incubation Time: < 3 hours
Sample Type: Serum, Plasma
Sample Size: 20 µL
Alternative Names: Asymmetric Dimethylarginine

Controls Included

Reference Values (Normal)
0.4 – 0.75 µmol/l (80 – 150 ng/ml)
Each laboratory should establish its own normal ranges

Assay Principle

The competitive ADMA (Asymmetric Dimethylarginine) ELISA uses the microtiter plate format. ADMA is bound to the solid phase of the microtiter plate. ADMA in the samples is acylated and competes with solid phase bound ADMA for a fixed number of rabbit anti-ADMA antiserum binding sites. When the system is in equilibrium, free antigen and free antigen-antiserum complexes are removed by washing. The antibody bound to the solid phase ADMA is detected by anti-rabbit/peroxidase and the substrate TMB / peroxidase reaction is monitored at 450 nm. The amount of antibody bound to the solid phase ADMA is inversely proportional to the ADMA concentration of the sample.

Products Related to ADMA ELISA Assay

ADMA Arginine ELISA Assay Kit

Homoarginine ELISA Assay Kit

SDMA ELISA Assay Kit News

For a Full Listing of Publications utilizing these ADMA ELISA Assays, click on the link below:
ADMA ELISA Kit Publications

Learn more about ADMA at Eagle Biosciences Biomarker Spotlight page dedicated to ADMA here:
ADMA Biomarker Spotlight

Additional Information

Assay Background

The vascular endothelium plays a central role in the regulation of vascular structure and function, mainly due to the formation of endothelium-derived nitric oxide (NO). NO has been named an “endogenous anti-atherogenic molecule” due to its diverse regulatory functions in vascular homeostasis.  NO is formed by the enzyme NO synthetase (NOS) from the amino acid precursor L-arginine. NOS activity can be down-regulated by asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NOS.

The effects of ADMA on NO synthesis and NO-mediated pathophysiological processes have been described in numerous experimental studies. Moreover, elevated ADMA levels in plasma have been found in clinical studies including samples with hyper­cholesterolemia, hypertension, chronic heart failure, chronic renal failure and other internal disorders.  Recent prospective and cross-sectional studies indicated that elevated ADMA levels are a risk factor for future cardiovascular events and total mortality. ADMA may have diagnostic relevance as a novel cardiovascular risk marker.

Cross Reactivity Data:

Structural related components were tested for possible interference with the antisera against ADMA used in the ADMA (Asymmetric Dimethylarginine) ELISA Assay kit method. The tested compounds were Arginine, Monomethylarginine (NMMA) und SDMA.


ED-50-Value (ng/ml)

Cross Reactivity (%)













Correlation with LC-MS-MS

The ADMA ELISA Assay Kit has been validated by comparing it with state-of-the-art LC-MS and GC-MS techniques. An extraordinarily good correlation of data was found (by comparison with LC-MS/MS, R = 0,984; p < 0.001; N = 29).  Cross-reactivities with other L-arginine analogues present in plasma and serum has been found to be negligible (L-NMMA, 1.93%; SDMA, 0.05%; L-arginine 0.03%).  The assay has also been validated for experimental purposes for use in mouse and rat plasma as well as in cell culture supernatants.  The figure shows the correlation of the ADMA (Asymmetric Dimethylarginine) ELISA Assay kit to the LC-MS-MS method. Comparative investigations to HPLC without subsequent MS lead to inconsistent results.




Approach. JSM. 47:149-155.

Lee, SJ;Lee, JS;Choi, MH;Lee, SE;Shin, DH;Hong, JM;, (2017). Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique. BMC Neurol, 17(1), 169-

Badran, M;Abuyassin, B;Golbidi, S;Ayas, N;Laher, I;, (2016). Uncoupling of Vascular Nitric Oxide Synthase Caused by Intermittent Hypoxia. Oxid Med Cell Longev, 20162354870-PubMed ID: 2784066

Baltgalvis, KA;White, K;Li, W;Claypool, MD;Lang, W;Alcantara, R;Singh, BK;Friera, AM;McLaughlin, J;Hansen, D;McCaughey, K;Nguyen, H;Smith, IJ;Godinez, G;Shaw, SJ;Goff, D;Singh, R;Markovtsov, V;Sun, TQ;Jenkins, Y;Uy, G;Li, Y;Pan, A;Gururaja, T;Lau, D;Park, Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice, Am. J. Physiol. Heart Circ. Physiol., 2014, Volume 36, Issue 8, page H1128-45,

Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP, Böger RH. Determination of ADMA using a novel ELISA assay.Clin. Chem. Lab. Med. 2004; 42: 1377-1383

Krempl TK, Kähler J, Maas R, Silberhorn L, Meinertz T, Böger RH.Elevation of asymmetric dimethylarginine (ADMA) in patients with unstable angina and recurrent cardiovascular events.Eur. Heart J. 2005; 26: 1846-1851

Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn L, Böger RH.Determination of a reference value for N,N-dimethyl-L-arginine in 500 subjects.Eur. J. Clin. Invest. 2005; 35 : 622-626

Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Münzel T. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study.Circ. Res. 2005; 97: e53-59

O`Dwyer MJ, Dempsey F, Crowley V, Kelleher D, McManus R, Ryan T.Septic shock correlates with ADMA levels which may be influenced by a polymorphism in DDAH II: a prospective observational study. Crit. Care 2006; 10: (5): R139 Antoniades C, Tousoulis D, Marinou K, Vasiliadou C, Tentolouris C, Bouras G, Pitsavos C, Stefanidis C. Asymmetrical dimethylarginine regulates endothelial function in methionine-induced but not in chronic homocystinemia in humans: effect of oxidative stress and proinflammatory cytokines Am. J. Clin. Nutr. 2006; 84: 781-788
Wang TZ., Chen WJ., Cheng WC., Lin JW., Chen MF., Lee YT.Relation of improvement in endothelium-dependent flowmediated vasodilation after Rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndromeAm. J. Cardiol. 2006; 9: 1057-1062

Wanby P., Nilsson I., Brudin L., Nyhammar I., Gustafsson I., Carlsson M. Increased plasma levels of asymmetric dimethylarginine in patients with carotid stenosis: no evidence for the role of the common FABBP2 A54T gene polymorphism >Acta Neurol. Scand. 2007; 115: 90-96

Konishi H, Sydow K, Cooke JP.Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury J. Am. Coll. Cardiol. 2007; 49: 1099-1105

Iribarren C, Husson G, Sydow K, Wang BY, Sidney S, Cooke JP. Asymmetric dimethyl-arginine and coronary artery calcification in young adults entering middle age: the CARDIA Study Eur. J. Cardiovasc. Prev. Rehabil. 2007; 14:222-229

Melikian N, Wheatcroft SB, Ogah OS, Murphy C, Chowienczyk PJ, Wierzbicki AS, Sanders TA, Jiang B, DuncanER, Shah AM, Kearney MT.Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young Black African men Hypertension 2007; 49: 873-877

Horowitz JD, Heresztyn T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: Methodological considerations. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007 Charitidou C, Farmakiotis D, Zournatzi V, Pidonia I, Pegiou T, Karamanis N, Hatzistilianou M, Katsikis I, Panidis D. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovarysyndrome Atherosclerosis 2007; in press.


Product Documents

Product Citations